Document is current
Any future updates will be listed below
-
Authors
Trauner, Doris https://orcid.org/0000-0002-1786-7597
Umlauf, Anya
Grelotti, David J.
Fitzgerald, Robert
Hannawi, Andrew
Marcotte, Thomas D.
Knight, Caitlin
Smith, Lauren
Paez, Gisselle
Crowhurst, Jennifer
Brown, Alyson
Suhandynata, Raymond T.
Lund, Kyle
Menlyadiev, Marlen
Grant, Igor
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04517799 at ClinicalTrials.govDocuments that mention this clinical trial
Cannabidiol (CBD) Treatment for Severe Problem Behaviors in Autistic Boys: A Randomized Clinical Trial
https://doi.org/10.1007/s10803-025-06884-y
-
Funding
Funding for this research was provided by:
National Institutes of Health (UL1TR001442)
- License Information
-
More Information
Article History
Accepted: 5 May 2025
First Online: 24 May 2025
Declarations
:
: The authors have no relevant financial or non-financial interests to disclose. GW Pharmaceuticals (now Jazz Pharmceuticals) provided the Epidiolex® and placebo for the study but had no input or control over any part of the research, and provided no compensation either financial or otherwise, to any of the investigators in the study.
: Informed consent was obtained from a parent or legal guardian according to standards set by the local Institutional Review Board. IRB approval was obtained prior to beginning the study and updated annually as mandated by the IRB (IRB# 181455). The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
